Interesting mechanism (sigma-1 + non-GABA anxiolysis) with Russian RCT base claiming GAD response without sedation or dependence. Western replication is absent. Same problem as most Russian pharmacology: methodology, blinding, and outcome assessment do not meet Western standards in most published trials, and the active-comparator data is weak. Subjective user reports range from "nothing felt" to "mild anti-anxiety with cognitive clarity." For Dylan with no anxiety indication, no current case. If anxiety control became a target, a clean placebo-controlled Western trial of fabomotizole would be needed before considering over established options (l-theanine, ashwagandha, low-dose SSRI under medical care). Stays WATCH-LIST.